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Oncogenic Ras transforms cells through the activa-
tion of multiple downstream pathways mediated by sep-
arate effector molecules, one of which is Raf. Here we
report the identification of a second ras-binding protein
that can induce cellular transformation in parallel with
activation of the Raf/mitogen-activated protein kinase
cascade. The Ral guanine nucleotide dissociation stim-
ulator (RalGDS) was isolated from a screen for Ras-
binding proteins that specifically interact with a Ras
effector-loop mutant, ras(12V,37G), that uncouples Ras
from activation of Raf1. RalGDS, like ras(12V,37G), co-
operates synergistically with mutationally activated
Raf to induce foci of growth and morphologically trans-
formed NIH 3T3 cells. RalGDS does not significantly
enhance MAP kinase activation by activated Raf, sug-
gesting that the cooperativity in focus formation is due
to a distinct pathway acting downstream of Ras and
parallel to Raf.
The Ras GTPases function as important nodes in signal
transduction networks regulating proliferation and differenti-
ation, integrating extracellular signals to a variety of down-
stream cellular responses. The importance of this role is high-
lighted by oncogenic ras, which can induce growth and
morphological transformation of many cell lines (1). It is be-
coming increasingly apparent that Ras activity is mediated
through multiple effector pathways (2–4). The best character-
ized pathway is the Raf/MAP1 kinase (mitogen-activated pro-
tein kinase) cascade where, upon Ras binding, Raf is activated
and in turn activates MAP kinase through the activation of
MEK (mitogen-activated or extracellular signal-regulated ki-
nase kinase) (5–8). MAP kinase activation is a critical step in
cellular transformation induced by oncogenic ras (9, 10).
Through the use of effector-specific ras mutants, which sep-
arate the ability of Ras to interact with different downstream
targets, we have previously shown that multiple Ras functions
can contribute to cellular transformation. Only one of these
involves Raf activation (3). ras(12V,37G) was defective in Raf1
binding and did not transform cells. However, ras(12V,37G)
retained activity that complemented the transformation defect
of a different ras mutant, ras(12V,35S). ras(12V,35S) could
bind Raf1 and activate MAP kinase, but was presumably de-
fective in other target interactions preserved by ras(12V,37G).
The cooperativity between ras(12V,37G) and ras(12V,35S) sug-
gested the presence of a novel pathway mediating Ras-induced
cellular transformation in parallel to Raf activation (3).
Here we report the identification of a mammalian ras-bind-
ing protein, RalGDS (11, 12, 13), that interacts with
ras(12V,37G). Using focus formation assays in NIH 3T3 cells,
we show that both ras(12V,37G) and RalGDS cooperate syner-
gistically with mutationally activated Raf to transform cells.
This cooperativity is not due to additive effects on MAP kinase
activation, suggesting that RalGDS, like ras(12V,37G), contrib-
utes to cellular transformation through an activity distinct
from activation of the Raf/MAP kinase cascade.
EXPERIMENTAL PROCEDURES
Plasmids—All ras variants used were in the vector pDCR, for mam-
malian expression, or pBTM116, for expression in yeast, as described
previously (3). pBTM116-Lamin was provided by A. Vojtek (14). pSRa-
raf-BXB was provided by A. Minden and M. Karin. pCEP4-RalGDS
contains the entire coding sequence of mouse ralGDS inserted as a
BamHI fragment into the BamHI site of pCEP4 (Invitrogen Corp.).
pCEP4-ralA(26A) and pCEP4-ralA(23V) were derived from pBTM116-
ralA(26A) and pBTM116-ralA(23V), respectively (15). Ral coding se-
quences were removed as blunt-ended XbaI-KpnI fragments and ligated
into pCEP4 at blunt-ended BamHI and KpnI sites.
Yeast Two-hybrid Screens and Tests—The yeast reporter strain L40
(14) was used for all two-hybrid analysis. A random-primed, size-se-
lected, mouse embryo cDNA library expressed as fusions to the VP16
activation domain (14) and an oligo(dT)-primed PC12 cDNA library
expressed as fusions to the GAL4 activation domain in pGADGH (pro-
vided by S. Tsui and S. Halegua) were screened for fusions that inter-
acted with ras(12V,37G) fused to the LexA DNA-binding domain. Ap-
proximately 10 million transformants were screened from each library.
Positives were tested for specificity of interaction by standard tech-
niques and sequenced (16).
Mammalian Cell Transfections—Stable transfections of NIH 3T3
cells were performed by the calcium phosphate precipitation method as
described (17). 24 h post-transfection, the cells were split into Dulbec-
co’s modified Eagle’s medium (ICN Biomedicals, Inc.) plus 5% calf
serum (Life Technologies, Inc.) for focus formation assays, and Dulbec-
co’s modified Eagle’s medium plus 10% calf serum supplemented with
0.5 mg/ml G418 sulfate (Life Technologies, Inc.). Foci of growth and
morphologically transformed cells were scored under magnification af-
ter 14 days of incubation in 5% serum. G418-resistant colonies were
counted after 10 days of growth in 10% serum plus G418. Transient
transfections were performed using LipofectAMINE (Life Technologies,
Inc.) according to the manufacturer’s protocols.
MAP Kinase Assays—Stably transfected NIH 3T3 cells were lysed in
a modified RIPA buffer supplemented with protease and phosphatase
inhibitors (18). ERK1 and ERK2 were immunoprecipitated from 200 mg
of total protein with the anti-ERK1 C-16 polyclonal antibody (Santa
Cruz Biotechnology, Inc.). The immunocomplex was incubated with 12
mg of myelin basic protein (MBP) in a kinase assay for 30 min at room
temperature (18). Reactions were separated by SDS-polyacrylamide gel
electrophoresis and visualized on a PhosphorImager (Molecular
* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
‡ To whom correspondence should be addressed: Dept. of Cell Biology
and Neuroscience, University of Texas Southwestern Medical Center,
5323 Harry Hines Blvd., Dallas, TX 75235-9039. Tel.: 214-648-2861;
Fax: 214-648-8694; E-mail: white08@utsw.swmed.edu.
** American Cancer Society Research Professor.
1 The abbreviations used are: MAP, mitogen-activated protein; MEK,
mitogen-activated or extracellular signal-regulated kinase kinase;
MBP, myelin basic protein; RalGDS, Ral guanine nucleotide dissocia-
tion stimulator.
Communication
THE JOURNAL OF BIOLOGICAL CHEMISTRY
Vol. 271, No. 28, Issue of July 12, pp. 16439–16442, 1996
© 1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Printed in U.S.A.
16439
 at Cold Spring Harbor Laboratory, on April 6, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Dynamics).
Antibodies and Protein Expression—Protein expression from exog-
enously introduced cDNAs was determined by Western blot analyses of
cell lysates. raf-BXB expression was detected, from 20 mg of total
protein, using the anti-Raf1 C-20 antibody (Santa Cruz Biotechnology,
Inc.). Endogenous, activated forms of ERK1 and ERK2 were detected,
from 20 mg of total protein, by using the 759B (Promega Corp.) antibody
that selectively recognizes activated MAP kinase. Total ERK1/ERK2
levels were detected using the anti-ERK1 C-16 antibody. RalA was
detected, from 20 mg of total protein, using a mouse anti-RalA mono-
clonal antibody from Transduction Laboratories.
RESULTS
ras(12V,37G) Interacts with RalGDS—To identify the effec-
tor molecule(s) that may mediate signaling from ras(12V,37G),
we used the yeast two-hybrid system to screen cDNA libraries
for clones that interact with ras(12V,37G) but not
ras(12V,35S). In this way, the previously characterized ras-
binding protein RalGDS was isolated from libraries derived
from mouse embryo and PC12 cells. RalGDS was originally
identified as a guanine nucleotide dissociation stimulator
(GDS) for the Ral GTPase (19). Human and rodent RalGDS
interact directly with Ras in a GTP-dependent manner (11–13),
and RalGDS has been shown to associate with Ras in COS cells
upon stimulation with epidermal growth factor (20). The two-
hybrid interactions of full-length RalGDS with ras(12V,37G)
versus other ras effector-domain mutants are shown in Fig. 1.
Although ras(12V,35S) does not interact with full-length Ral-
GDS, a truncated version of RalGDS, expressing amino acids
703–814, was isolated from the mouse embryo library which
interacts with both ras(12V,37G) and ras(12V,35S) (data not
shown). This suggests that the specificity of the RalGDS-Ras
interaction is affected by residues outside of the minimal ras
interaction domain (12). A different ras effector mutant
rasV12C40 did not interact with any form of RalGDS isolated
(Fig. 1 and data not shown).
ras(12V,37G) and RalGDS Cooperate with Activated raf to
Transform Cells—ras(12V,37G) is defective in Raf1 binding,
but retains a function that cooperates with Raf1 to transform
cells (3). The binding of RalGDS with ras(12V,37G) suggests
the possibility that RalGDS may partially or fully mediate this
function. To test this, we compared the abilities of RalGDS and
ras(12V,37G) to enhance focus formation induced by activated
raf. raf-BXB is a Raf1 variant with a deletion of the amino-
terminal regulatory domain containing the Ras-binding site
(14, 21). This results in a mutationally activated protein that
signals constitutively to downstream components (21). NIH
3T3 cells were transfected with rasV12, raf-BXB, ras(12V,37G),
and wild-type RalGDS alone and in the indicated combinations
(Fig. 2). raf-BXB alone induced a low level of focus formation.
Both RalGDS and ras(12V,37G) had no focus forming activity
when expressed alone or together. However, ras(12V,37G)
acted synergistically with raf-BXB to transform cells, resulting
in an approximately 8-fold induction of focus formation above
the level observed with raf-BXB alone. Similarly, RalGDS
acted synergistically with raf-BXB to transform cells, resulting
in an approximately 12-fold induction of focus formation above
the level observed with raf-BXB alone. raf-BXB expression
levels, as determined by Western blotting of pooled G418-re-
sistant colonies, were equivalent in cells transfected with raf-
BXB alone and in combination with ras(12V,37G) or RalGDS
(data not shown).
Ectopic Expression of RalGDS Does Not Contribute to MAP
Kinase Activation by raf-BXB—The activation of MAP kinase is
an important step in cellular transformation induced by Ras
and Raf (9, 10). It is possible that the cooperativity in focus
formation between ectopically expressed RalGDS and raf-BXB
converges at the level of MAP kinase activation. To test this,
the MAP kinases ERK1 and ERK2 were immunoprecipitated
from pooled G418-resistant colonies derived from cells trans-
fected with pDCR-ras(12V) or pSRa-raf-BXB alone and in com-
FIG. 1. Two-hybrid interactions between ras mutants and Ral-
GDS. Ras variants and lamin, as a control, were expressed as fusions to
the LexA DNA-binding domain. RalGDS was expressed as a fusion to
the GAL4 activating domain. Transformants, from the yeast reporter
strain L40, selected to express GAL4 activating domain-RalGDS and
the indicated LexA DNA-binding domain fusions, were tested for the
ability to grow on media lacking histidine. Growth on the selective plate
indicates a positive two-hybrid interaction. Transformants that were
His1 also gave a positive indication of b-galactosidase activity using
filter assays (data not shown). At least four independent transformants
were tested for each pair. FIG. 2. ras(12V,37G) and RalGDS cooperate with raf-BXB totransform cells. NIH 3T3 cells were transfected with the constructs
expressing the indicated proteins. Each transfection included the ap-
propriate empty vector(s) as needed to achieve equivalent DNA concen-
trations and to allow G418 selection. Focus formation frequency for
each transfection was determined as number of foci per number of
G418-resistant colonies, normalized to the focus formation frequency
induced by ras(12V), which was set at 100. Ras variants were intro-
duced (100 ng/transfection) in pDCR which contains the G418 resist-
ance gene. RalGDS was introduced (500 ng/transfection) in pCEP4.
raf-BXB was introduced (100 ng/transfection) in pSRa. Transfections
with only empty vectors yielded no foci. Results shown represent one
experiment with each transfection performed in duplicate. Error bars
indicate the variation observed between the duplicate transfections.
Three additional experiments yielded similar results.
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bination with pCEP4-RalGDS. The number of colonies derived
from individual transfections were equivalent (;250/plate). Ac-
tivity of the immunoprecipitated ERK1 and ERK2 was assayed
by in vitro phosphorylation of MBP. The level of MAP kinase
activation in cells expressing raf-BXB was similar to that in
cells expressing ras(12V). Coexpression of RalGDS with raf-
BXB resulted in no detectable induction of MAP kinase above
the level observed with raf-BXB alone (Fig. 3A).
Transient transfection assays yielded similar results. To de-
tect activation of endogenous MAP kinase in transiently trans-
fected cells, it was necessary to use the 759B antibody which
selectively recognizes the activated phosphorylated forms of
ERK1 and ERK2. Cells transiently expressing RalGDS or
ras(12V,37G) showed no increase in the levels of activated
MAP kinase as compared to cells transfected with empty vec-
tors. Importantly, RalGDS and ras(12V,37G) did not signifi-
cantly enhance the level of activated MAP kinase induced by
raf-BXB. Total levels of cellular MAP kinase were equivalent
among transfections (Fig. 3B).
Contribution of the Ral GTPase to transformation by Ras and
Raf—RalGDS stimulates guanine nucleotide exchange on the
Ras-related GTPase Ral (19). Therefore, the promotion of cel-
lular transformation by RalGDS may be a consequence of Ral
activation. To test this, we examined the contribution of Ral to
focus formation by Ras and Raf.
ralA(23V) has a mutation resulting in a defective intrinsic
GTPase activity homologous to the ras(12V) activating muta-
tion (22). Expression of pCEP4-ralA(23V) resulted in a 3-fold
elevation of total RalA protein but did not cooperate with
raf-BXB to transform cells (Fig. 4). This lack of cooperativity
suggests that RalGDS may contribute to raf-BXB-induced fo-
cus formation through a RalA-independent mechanism. Alter-
natively, the 23V mutation may not result in the same degree
of functional activation of RalA as ectopic expression of
RalGDS.
ralA(26A) contains a mutation with structure and sequence
homology to the dominant negative mutant ras(15A) (23).
ras(15A) has been shown to form unproductive complexes with
Ras guanyl nucleotide exchange factors and is predominantly
in the GDP-bound state (24, 23). We hoped that expression of
ralA(26A) would inhibit cellular Ral function by sequestering
Ral guanyl nucleotide exchange factors in a manner analogous
to the block of cellular Ras function that occurs upon expression
of ras(15A). Expression of pCEP4-ral(26A) resulted in a 2.5-fold
elevation in total detectable RalA protein. ralA(26A) had no
significant effect on focus formation induced by raf-BXB.
ralA(26A) expression did result in a small but reproducible
reduction in foci induced by ras(12V) and by coexpression of
raf-BXB and ras(12V,37G) (Fig. 4). This reduction may be a
result of sequestration of RalGDS through unproductive bind-
ing to ralA(26A). Consistent with this, ralA(26A) interacts with
RalGDS in the yeast two-hybrid system whereas wild-type
RalA and ralA(23V) give no detectable interaction (data not
shown).
DISCUSSION
ras(12V,37G) is defective in Raf1 interaction and cellular
transformation. However, ras(12V,37G) does retain an activity
that complements the transformation defect of a different Ras
mutant, ras(12V,35S). ras(12V,35S) binds Raf1, but is presum-
ably defective in other target interactions that mediate cellular
FIG. 3. RalGDS does not contribute to MAP kinase activation
by activated raf. A, MAP kinase activity in stable transfected cell
lines, expressing the indicated proteins, was measured by MBP phos-
phorylation using anti-ERK1/ERK2 immune complexes. Numbers indi-
cate fold elevation relative to vector-transfected cells. raf-BXB expres-
sion levels were equivalent in cells transfected with raf-BXB alone or in
combination with RalGDS (data not shown). Two additional experi-
ments yielded similar results. B, NIH 3T3 cells were transiently trans-
fected with the indicated constructs (1 mg/transfection) and empty vec-
tor as required (2 mg/transfection of total DNA). The level of activated
cellular MAP kinase was measured by Western blotting using the
polyclonal antibody 759B which selectively recognizes the activated
phosphorylated forms of ERK1 and ERK2. Blots were stripped and
reprobed with the C-16 antibody which recognizes both active and
inactive forms of ERK1 and ERK2. A repeated experiment yielded
similar results.
FIG. 4. Contribution of ral(26A) and ral(23V) mutants to focus
formation induced by activated ras and raf. NIH 3T3 cells were
transfected with plasmids expressing the indicated proteins, and focus
formation frequencies were determined as described in Fig. 2. Ras
variants, RalGDS, and raf-BXB were introduced as described in Fig. 2.
Ral mutants were introduced (500 ng/transfection) in pCEP4, resulting
in a 2- to 3-fold elevation of total Ral protein as determined by Western
blot (data not shown). Results represent one experiment with each
transfection performed in duplicate. Error bars indicate the variation
observed between the duplicate transfections. Two additional experi-
ments yielded similar results.
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transformation. The transformation defect of ras(12V, 37G) is
rescued by coexpression of a Raf1 mutant that rescues binding
to ras(12V,37G). We have interpreted this as evidence that Ras
transforms cells through the activation of Raf1 as well as other,
as yet unidentified, molecules (3). Here, we show that the
ras-binding protein RalGDS interacts with ras(12V,37G) but
not ras(12V,35S), suggesting that it may mediate the comple-
mentary transformation activity of ras(12V,37G). Consistent
with this, RalGDS, like ras(12V,37G), cooperates with muta-
tionally activated raf to transform cells.
While the results described here establish RalGDS as a pos-
itive regulator of transformation, it remains to be demon-
strated that this activity is mediated by Ras interaction. In
addition, RalGDS is not the only candidate Ras effector other
than Raf which may mediate Ras-induced cellular transforma-
tion. Additional Ras-binding proteins have been identified, in-
cluding phosphatidylinositol-3-OH kinase (2), AF6 (25), Rin-1
(26), NF1 (27), zPKC (28), and MEK kinase 1 (29), some or all
of which may have roles in mediating Ras activity, including
induction of cellular transformation.
Raf1 activates MAP kinase through direct binding and acti-
vation of MEK, a MAP kinase kinase (8). MAP kinase activa-
tion is an important step in the induction of cellular transfor-
mation by oncogenic ras (9, 10). The complementary
transforming activity of RalGDS does not appear to converge at
the level of MAP kinase activation, as it does not activate MAP
kinase and does not enhance activation of MAP kinase by
activated Raf. This suggests that RalGDS contributes to cellu-
lar transformation by activating a pathway that is distinct
from the Raf-MAP kinase cascade.
Obvious candidates for targets that mediate RalGDS trans-
forming activity are the Ral GTPases (30). The use of “activat-
ed” and “dominant negative” mutants of RalA was unsuccessful
in revealing a role for Ral GTPases in Ras-induced cellular
transformation. Similar experiments with RalB mutants were
also negative (data not shown). However, while this manu-
script was in preparation, Urano et al. (31) published observa-
tions that ralA(72L) cooperated with ras(12V) to transform
cells, and ralA(28N) interfered with cellular transformation by
both ras(12V) and v-raf. Parallel studies with these same re-
agents have not been done by us, and we cannot rule out a role
for RalA in mediating the activities we observe with RalGDS.
Further studies are underway, using mutants of RalGDS that
effect Ral binding and guanyl nucleotide exchange, as well as
RalGDS mutants that restore interaction with ras mutants,
that should clarify the roles of RalGDS and Ral in mediating
Ras-induced cellular transformation.
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